At the recent AAPS PharmSci 360 conference in San Antonio, Texas, Corey Bloom from Lonza captivated the audience with insights on Amorphous Solid Dispersion (ASD) development. This crucial topic delves into the realm of drug delivery technology selection and the significance of establishing partnerships with Contract Development and Manufacturing Organizations (CDMOs).
In the current landscape of pharmaceuticals, the prevalence of low solubility compounds poses a significant hurdle, with approximately 90% of preclinical compounds facing bioavailability challenges. This surge in complex chemical entities entering drug pipelines emphasizes the critical need for tailored formulation and process strategies early in the developmental journey. The right approach can expedite clinical trial progress and pave the way for successful commercial manufacturing, while a suboptimal strategy may lead to prolonged timelines and potential setbacks.
To navigate the complexities of formulation and process development effectively, a methodical selection of technology to enhance bioavailability is paramount. Employing a science-based approach that incorporates factors like the target product profile, drug properties, and absorption modeling can streamline decision-making. Leveraging in-silico tools and biomodeling aids in predicting compound performance and defining formulation goals, optimizing the path from preclinical phases to commercialization.
Amorphous solid dispersions (ASDs) emerge as a versatile solution due to their ability to enhance drug solubility and stability across a spectrum of properties. By breaking free from a crystalline lattice structure and incorporating enhancing excipients, ASDs can significantly boost drug solubility, paving the way for improved bioavailability and patient outcomes. Techniques like hot-melt extrusion (HME) and spray drying offer distinct advantages based on API properties and developmental stage, with HME standing out for its scalability and sustainability benefits.
When dealing with challenging compounds that exhibit low solubility or crystallization tendencies, a well-defined roadmap from preclinical to commercial production is essential. Specialized techniques such as temperature adjustments and processing aids can facilitate the manufacture of intricate compounds, while a focus on scalability and process optimization early on can save valuable time and resources.
Efficiency in drug development hinges on transitioning from trial-and-error approaches to rational design, emphasizing the importance of partnership with experienced CDMOs. By aligning with organizations that boast diverse formulation capabilities and a proven track record in scaling up formulations, pharmaceutical companies can mitigate risks of delays and reformulations, ensuring a smoother transition from development to commercialization.
In conclusion, the journey of Amorphous Solid Dispersion development is a strategic blend of science, technology, and collaboration, with the potential to revolutionize drug delivery for challenging compounds. By embracing cutting-edge methodologies and forging strong partnerships, the pharmaceutical industry can overcome solubility barriers and drive innovation towards enhanced patient care.
- Rational design accelerates pharmaceutical formulation efficiency.
- Specialized techniques optimize challenging compound manufacturing.
- Collaboration with experienced CDMOs mitigates risks and streamlines development processes.
Tags: biopharma, clinical trials, scale up, drug delivery, formulation, process development
Read more on pharmtech.com